Evidence map›Paper›PMID 32169105›Full record

ReviewMicrobiome2020

Gut microbiota and cardiovascular disease: opportunities and challenges.

Negin Kazemian, Morteza Mahmoudi, Frank Halperin, Joseph C Wu, Sepideh Pakpour

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microbiome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed, 8 pooled it
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

211 citing papers in PubMed, 8 syntheses or guidelines pooled it, 372 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Negin KazemianSchool of Engineering, University of British Columbia, Kelowna, Kelowna, BC, Canada.
Morteza MahmoudiDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, USA. mahmou22@msu.edu.
Frank HalperinCardiology Interior Health, Kelowna, BC, Canada.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sepideh PakpourSchool of Engineering, University of British Columbia, Kelowna, Kelowna, BC, Canada. sepideh.pakpour@ubc.ca.
Cardiovascular Institute of the South · USInterior Health · CAKelowna General Hospital · CAMichigan State University · USUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary artery disease (CAD) is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Over the past decade, it has become clear that the inhabitants of our gut, the gut microbiota, play a vital role in human metabolism, immunity, and reactions to diseases, including CAD. Although correlations have been shown between CAD and the gut microbiota, demonstration of potential causal relationships is much more complex and challenging. In this review, we will discuss the potential direct and indirect causal roots between gut microbiota and CAD development via microbial metabolites and interaction with the immune system. Uncovering the causal relationship of gut microbiota and CAD development can lead to novel microbiome-based preventative and therapeutic interventions. However, an interdisciplinary approach is required to shed light on gut bacterial-mediated mechanisms (e.g., using advanced nanomedicine technologies and incorporation of demographic factors such as age, sex, and ethnicity) to enable efficacious and high-precision preventative and therapeutic strategies for CAD.

Indexed as

Gastrointestinal MicrobiomeAnimalsBacteriaCardiovascular DiseasesCholesterolCoronary Artery DiseaseFecesHumansCholesterol

Identifiers

PMID32169105
PMCPMC7071638
OpenAlexW3010928772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.